2023 has been a mild year for public medtech companies. Share prices are either keeping pace with major indexes or, in the case of sectors that boomed during the COVID-19 pandemic, running below. Earnings estimates show a recovery in 2024 and 2025. PitchBook’s new Q2 2023 Medtech Public Comp Sheet and Valuation Guide tracks stock performance, valuations, and market caps—as well as forecasts for revenue, EBITDA, and earnings per share—for key publicly traded companies. For this quarter’s guide, all tables and charts are presented in spreadsheets for ease of use.
Read the full article: Medtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q2-2023-medtech-public-comp-sheet-and-valuation-guide